Overview
Silin Zeng practices practicing medicine in Shenzhen, China.
Their clinical expertise encompasses Anti-NMDA Receptor Encephalitis, Spinocerebellar Ataxia Type 6, Encephalitis, and Teratoma of the Mediastinum.
They are actively involved in clinical research, co-authoring 9 peer reviewed articles.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Silin Zeng
Is Silin Zeng a top-rated expert for Anti-NMDA Receptor Encephalitis?
MediFind is an objective health platform that identifies experts based on real-world data. Silin Zeng is classified as an Experienced expert for Anti-NMDA Receptor Encephalitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Silin Zeng participate in research or clinical trials?
Yes. Silin Zeng has published 9 articles and abstracts on conditions like Anti-NMDA Receptor Encephalitis. You can view a list of Silin Zeng's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Anti-NMDA Receptor Encephalitis
- EncephalitisZeng isExperienced. Learn about Encephalitis.
- Spinocerebellar Ataxia Type 6
- Teratoma of the MediastinumZeng isExperienced. Learn about Teratoma of the Mediastinum.